



Attorney Docket: 24390

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

SHINITZKY, et al.

GAU: 1647

Serial Number: 09/647,457

Examiner: Unknown

Filed: November 29, 2000

Title: **ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE**

**TRANSMITTAL LETTER**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter;
- (2) Information Disclosure Statement;
- (3) PTO Form 1449 with Two (2) References;
- (4) Document stating citation of the Two (2) References by the European Examiner dated September 16, 2004.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account Number 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

By:

Date: January 13, 2005

**NATH & ASSOCIATES PLLC**  
1030 15<sup>th</sup> Street N.W., 6<sup>th</sup> Floor  
Washington, D.C. 20005-1503

Gary M. Nath  
Registration Number 26,965  
Lee C. Heiman  
Registration Number 41,827  
Customer Number 20529

Tel. (202) 775-8383  
Fax. (202) 775-8396

GMN/LCH/le



Attorney Docket: 24390

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

SHINITZKY, et al.

GAU: 1647

Serial Number: 09/647,457

Examiner: Unknown

Filed: November 29, 2000

Title: **ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE**

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

☒ a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

☐ b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☐ ii. a check in the amount required by 37 C.F.R. 1.17(p).

☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

☐ Certification report(e) below; and

☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[ ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[ ] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[ ] Appropriate certification is attached.

[~~xxx~~] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[~~xxx~~] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[ ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

or

[ ] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents

have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**



By:


Date: January 13, 2005

**NATH & ASSOCIATES PLLC**  
1030 15<sup>th</sup> Street N.W., 6<sup>th</sup> Floor  
Washington, D.C. 20005-1503

Gary M. Nath  
Registration Number 26,965  
Lee C. Heiman  
Registration Number 41,827  
Customer Number 20529

Tel. (202) 775-8383  
Fax. (202) 775-8396

GMN/LCH/le



FORM PTO-1449

**INFORMATION DISCLOSURE CITATION**Attorney Docket:  
24390Serial Number:  
09/647,457Applicant:  
SHINITZKY, et al.Filing Date:  
September 29, 2000GAU:  
1647**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	A1						
	A2						
	A3						
	A4						
	A5						
	A6						

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Sub-Class	Translation
	A7						
	A8						
	A9						
	A10						
	A11						
	A12						
	A13						

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	A14		Vermuyten, K., et al., "Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay", <u>Clinica. Chimica. Acta.</u> , Vol. 187, pp. 69-78, (1990).
	A15		Database NCBI on: <u>www.ncbi.nlm.nih.gov</u> , accession no. NP 001966 (human neuron specific enolase), pp. 1-3, (2004).
	A16		

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.